您要查找的是不是：
- The relative factors of CRP and prediction of major adverse cardiac events (MACE) for coronary disease (CHD). 冠心病病人CRP的影响因素及对主要不良心脏事件(MACE)的预测。
- Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. 他汀类药物治疗可能降低代谢综合征患者的主要不良心血管事件发生率，但是证据有限。
- Main Outcome Measures : Survival free of major adverse cardiac events defined as cardiac death, nonfatal MI, and/or symptom-driven revascularization. 主要结果量度：无主要严重心脏意外（定义为心脏死亡、非致命的MI和/或症状驱动的血管形成术）的生存期。
- The main end point of the trial was a 30-day incidence of major adverse cardiac events (death, myocardial infarction, or unplanned revascularization). 试验的主要临床终点为30天主要不良心脏事件发生率（死亡，心肌梗死，计划外血运重建）。
- Conclusion: This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events. 结论：此研究支持将他汀类药物用于治疗患有代谢综合征的微量白蛋白尿受试者，以降低主要不良心血管事件发生率。
- We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjectswith themetabolic syndrome. 评估了普伐他汀治疗对患有代谢综合征的微量白蛋白尿患者的主要不良心血管事件发生率的影响。
- NEW YORK( Reuters Health) Dec27- Coronary artery disease patients who discontinue their aspirin face an increased risk for major adverse cardiac events, according to a report in the November European Heart Journal. 纽约（透社健康版）2月27日－《欧洲心脏杂志》11月刊报道，冠状动脉疾病患者中断服用阿司匹林将导致发生主要心脏不良事件的风险增加。
- This study compared death and major adverse cardiac events (MACE)(re- infarction,heart failure,revascularization,cardiogenic shock) in 1 year between groups receiving and not receiving large dose meto- prolol. 观察发病1 a内两组死亡率和MACE事件(再发心肌梗死、心源性休克、需住院的心力衰竭、再血管化治疗)发生情况。
- Methods 120 patients with ACS and 94 healthy people were adopted in the study. Plasma CRP were measured and the risk for major adverse cardiac events(MACE) at 30 days and 3 months were analyzed. 方法测定120例ACS患者和94例健康对照组的血浆CRP水平,随访ACS患者住院期间、30天以及3个月死亡事件以及MACE发生率。
- Relation of C-reactive protein to the stability of coronary artery lesions and major adverse cardiac events 心绞痛患者C反应蛋白与冠状动脉病变稳定性和心脏事件关系的探讨
- Keywords drug eluting stent;Sirolimus;Paclitaxel;major adverse cardiac event;target vessel revascularization; 药物涂层支架;西罗莫司;紫杉醇;主要不良心脏事件;目标血管重建;
- The incidence of major adverse cardiac events and intravascular restenosis in Firebird and Taxus Express2 groups was fewer than bare metal stent group (P < 0.05); 主要心脏不良事件、血管内再狭窄，雷帕霉素组和紫杉醇组均少于裸支架组（P < 0.;05）；
- Major adverse cardiac events 严重心脏事件
- major adverse cardiac event 主要不良心脏事件
- The major adverse effect of ribavirin is hemolytic anemia. 利巴韦林的主要副作用是溶血性贫血。
- adverse cardiac events 严重心脏意外
- Recent studies have shown that hypothermia triples the incidence of major cardiac events. 摘要最近报告认为低体温可增加心脏并发症的发生率。
- In both groups, quantitative coronary angiography was performed, and target vessel revascularization (TVR) and major adverse cardiovascular events (MACE) were documented. 随访靶血管再次成形率 (TVR)和主要不良心血管事件 (MACE)发生率。
- But they say that despite these limitations, patients and providers should consider the potential for serious adverse cardiac effects of treatment with rosiglitazone. 但他们说，尽管有这些限制，病人和供者应考虑到用罗格列酮治疗中潜在的严重不良的心脏治疗。
- There were apparent baldness in FAM group,and 2 patients hnd cardiac events. FAM组有明显的脱发 ,2例出现心脏毒性反应。
